Approval of the world’s first BNCT drug Steboronine®
It was gratifying that Japan Ministry of Health, Labour and Welfare approved the world’s first boron drug Steboronine® developed by STELLA PHARMA CORPORATION on March 25, 2020. 
STELLA PHARMA CORPORATION conducted Phase Two trial (company-initiated clinical trial) in collaboration with Sumitomo Heavy Industries and Southern TOHOKU BNCT Research Center since December 2015. Steboronine® will be utilized in Boron Neutron Capture Therapy (BNCT), which not only gives another option to the oncologists, but benefits the treatment of locally unresectable recurrent or unresectable advanced head and neck cancer.


Printer Friendly